{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"30","value":"23.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Phase II - To determine the median overall survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II: Treatment at Maximum Tolerated Dose (MTD).","id":"OG000","title":"II: Maximum Tolerated Dose - Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"All participants who received ruxolitinib therapy","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}